---
layout: default
title: Titanium Dioxide
parent: 僅模型預測 (L5)
nav_order: 1234
evidence_level: L5
indication_count: 10
---

# Titanium Dioxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Titanium Dioxide: From [No Approved Indication] to Drug-Induced Osteoporosis

## One-Sentence Summary

> Titanium dioxide is a pharmaceutical excipient/colorant with no approved therapeutic indication and no known mechanism of action.
> The TxGNN model predicts a possible association with **Drug-Induced Osteoporosis**,
> but **0 clinical trials** and **0 publications** currently support this direction — the prediction is unvalidated by any biological or clinical evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not applicable (excipient/colorant, no therapeutic indication) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Titanium dioxide is not a therapeutic drug in the conventional sense — it is widely used as an inert excipient (opacifier/colorant) in tablet coatings and other pharmaceutical formulations. It has no established pharmacodynamic activity, receptor target, or metabolic pathway relevant to bone metabolism.

The TxGNN model's top prediction (Drug-Induced Osteoporosis, score 99.9998%) is derived purely from knowledge-graph relational patterns rather than any known biological mechanism. Because titanium dioxide's original indications list is empty and its MOA is a confirmed data gap, there is no pharmacological basis to explain why this compound would influence osteoporosis pathophysiology.

Reviewing all 10 top-ranked predicted indications for this candidate (osteoporosis, diabetic retinopathy, and multiple cataract subtypes), the pattern is consistent: high TxGNN scores are not accompanied by any clinical trials, and the sparse literature identified (5 papers under diabetic retinopathy) uses TiO2 nanoparticles purely as **laboratory/imaging tools** (e.g., extracellular vesicle purification, fluorescein conjugate imaging), not as therapeutic agents. This strongly suggests the TxGNN association reflects graph-topology co-occurrence (e.g., TiO2 nanoparticles appearing frequently in biomedical research contexts) rather than genuine drug-disease therapeutic relevance.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

No literature is available for the top-ranked indication (Drug-Induced Osteoporosis). For reference, the rank-2 prediction (diabetic retinopathy) returned 5 papers, but all are non-therapeutic technical/methods papers (TiO2 nanoparticles used as tools for EV purification, retinal imaging agents, or in a general nanoparticle-diabetes mechanism review) rather than evidence supporting therapeutic use — see table below for completeness:

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [41637842](https://pubmed.ncbi.nlm.nih.gov/41637842/) | 2026 | Review | J Trace Elem Med Biol | Reviews metallic nanoparticles (incl. TiO2) as tools/agents in diabetes research; not a treatment study |
| [39566751](https://pubmed.ncbi.nlm.nih.gov/39566751/) | 2025 | Technical/Imaging | Methods (San Diego) | TiO2 nanoparticle-fluorescein conjugates evaluated as imaging agents for fundus angiography, not therapy |
| [38078945](https://pubmed.ncbi.nlm.nih.gov/38078945/) | 2023 | Methods/Technical | Analytical Chemistry | TiO2 microparticles used as a purification tool for circulating RNA analysis |
| [36197877](https://pubmed.ncbi.nlm.nih.gov/36197877/) | 2022 | Methods/Technical | Analytical Chemistry | TiO2 microparticles used to purify plasma extracellular vesicles for biomarker discovery |
| [20059246](https://pubmed.ncbi.nlm.nih.gov/20059246/) | 2009 | Technical/Device | J Biomed Optics | Eye phantom device for retinal oximetry calibration; unrelated to TiO2 pharmacology |

None of these papers provide treatment or efficacy evidence for any predicted indication.

---

## US Market Information

No approved marketing authorizations found. Titanium dioxide is currently **未上市 (Not Marketed)** with 0 total licenses on record for this candidate.

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: Regulatory warning/contraindication data (DG001) is flagged as a **Blocking** data gap — this candidate has not entered safety screening (S1), and MOA data (DG002) is a **High**-severity gap affecting mechanistic assessment.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No original indication, no MOA, no clinical trials, and no supportive literature exist for any of the 10 top predicted indications. The high TxGNN scores reflect knowledge-graph pattern association only (Evidence Level L5) and lack any biological plausibility check — this candidate has not progressed past decision stage S0.

**To proceed, the following is needed:**
- Resolve DG001 (blocking): obtain TFDA/FDA label warnings and contraindications before any safety screening (S1) can begin
- Resolve DG002: obtain confirmed mechanism of action from DrugBank or primary literature
- Independent pharmacological plausibility assessment of titanium dioxide as a therapeutic agent (not merely an excipient) for bone metabolism, ophthalmic, or metabolic indications
- If no plausible MOA can be established, recommend excluding this candidate from further repurposing evaluation rather than continuing to Hold
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

